About: Selection of an aminoglycoside antibiotic for administration to horses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Selection of an aminoglycoside antibiotic for administration to horses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Selection of an aminoglycoside antibiotic for administration to horses
Creator	Baggot, J Love, Daria Raus, R Rose+, R
Source	PMC
abstract	The serum concentrations of the aminoglycosides neomycin, kanamycin and streptomycin were determined after intravenous (iv) and intramuscular (im) administration. These values were then related to the minimum inhibitory concentrations (MIC) of a number of equine pathogenic bacteria to determine the duration of therapeutic serum concentrations of the aminoglycosides in the horse. Pharmacokinetic analysis of the data using neomycin as the example revealed a mean (± sd) peak serum concentration of 23.2 ± 10.2 μg/ml present at 30 mins, and at 8 h the serum concentration was 2.8 ± 0.8 μg/ml. From the pharmacological analysis of concentration‐time data it was shown that neomycin was very rapidly absorbed from the im injection site, with an absorption half‐time of 0.16 ± 0.05 and was well absorbed (systemic availability was 73.7 ± 26.9 per cent). A peak tissue level, which represented 40 per cent of the amount of drug in the body, was obtained at 32 mins after injection of the drug. At 8 h, the fractions of the dose in the central and peripheral compartments of the model were 1.5 per cent and 2.5 per cent respectively, and 96 per cent was the cumulative amount eliminated up to that time. Based on the MIC values of the majority of isolates of Corynebacterium equi, and only a few isolates of Klebsiella pneumoniae, Escherichia coli, Salmonella typhimurium and Streptococcus equi, one would expect a serum concentration of more than 2 μg neomycin/ml up to 8 h following im dosage (10 mg/kg) to be therapeutically effective.
has issue date	2010-04-23(xsd:dateTime)
bibo:doi	10.1111/j.2042-3306.1985.tb02034.x
bibo:pmid	3979370
has license	no-cc
sha1sum (hex)	314d309c4d814a36f860bcaebe99428c33209b50
schema:url	https://doi.org/10.1111/j.2042-3306.1985.tb02034.x
resource representing a document's title	Selection of an aminoglycoside antibiotic for administration to horses
has PubMed Central identifier	PMC7197637
has PubMed identifier	3979370
schema:publication	Equine Vet J
resource representing a document's body	covid:314d309c4d814a36f860bcaebe99428c33209b50#body_text
is schema:about of	named entity 'concentration' named entity 'Corynebacterium' named entity 'drug' named entity 'serum' named entity 'aminoglycoside antibiotic' named entity 'MAJORITY' named entity 'USING' named entity 'ABSORPTION' named entity 'MIC' named entity 'NUMBER OF' named entity 'KLEBSIELLA PNEUMONIAE' named entity 'KANAMYCIN' named entity '1.5' named entity 'MG%' named entity 'PERIPHERAL' named entity 'THERAPEUTIC' named entity 'RAPIDLY' named entity 'SERUM' named entity 'CENTRAL' named entity 'cent' named entity 'concentrations' named entity 'neomycin' named entity 'Pharmacokinetic' named entity 'values' named entity 'inhibitory' named entity 'Escherichia coli' named entity 'concentrations' named entity 'majority' named entity 'peak' named entity 'cent' named entity 'pharmacological' named entity 'neomycin' named entity 'Pharmacokinetic' named entity 'serum' named entity 'tissue level' named entity 'Streptococcus equi' named entity 'Corynebacterium equi' named entity 'Staphylococcus aureus' named entity 'Enterobacter' named entity 'drug administration' named entity 'renal excretion' named entity 'antibiotic' named entity 'pathogens' named entity 'nutrient broth' named entity 'neomycin' named entity 'MIC' named entity 'neonatal' named entity 'antimicrobial agent' named entity 'MICs' named entity 'Klebsiella pneumoniae' named entity 'broad spectrum' named entity 'neomycin' named entity 'Salmonella typhimurium' named entity 'organism' named entity 'organism' named entity 'neomycin' named entity 'ototoxicity' named entity 'gentamicin' named entity 'aminoglycosides' named entity 'gentamicin' named entity 'drug administration' named entity 'neomycin' named entity 'pharmacokinetic' named entity 'pharmacokinetic' named entity 'minimum inhibitory concentration' named entity 'aminoglycosides' named entity 'antibiotic' named entity 'domestic animals' named entity 'tissue level' named entity 'toxicity' named entity 'Systemic administration' named entity 'systemic infection' named entity 'kanamycin' named entity 'non-linear regression' named entity 'Neonatal' named entity 'serum' named entity 'neomycin' named entity 'Escherichia coli'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software